Primary Outcome Measures:
- Search for IRGM mutations and compare the frequency of these mutations.
Patients who receive surgical resection for intestinal MC have, within six months after surgery gastrointestinal endoscopy for judging the endoscopic recurrence and modify treatment if necessary. This quantifies the endoscopic recurrence of i0 to i4 classified according to the Rutgeerts score (45). Patients who have a score ≥ i2 have a severe endoscopic recurrence. We will compare the prevalence of sick with a score ≥ i2 in patient groups with or without mutation in the gene IRGM. The investigators will look for the existence of a mutation in the gene IRGM, Atg16 and IL23R. The mutation in the gene IRGM being the main prognostic factor, mutations in the genes IL23R Atg16 and prognostic factors constituting secondary.
Secondary Outcome Measures:
- To assess the prevalence of mutations IGRM in a prospective series of 200 patients operated
The prevalence of mutations IGRM, Atg16 and IL23 will be determined
- Determine whether there are phenotypic characteristics of the disease associated with mutations of IGRM
The investigators will compare the frequency of postoperative recurrence in patients who have a mutation in the genes IL23 and Atg16
- Determine whether there are pathological features associated with mutations of IGRM.
The investigators will determine if the main phenotypic characteristics of CD (age of onset, time between diagnosis and surgery, use of immunosuppressive and biologic therapies, smoking localization of the disease, etc..) Are associated with increased prevalence of mutations of IGRM, Atg16 and IL23R.
Lesional tissue samples and healthy in cryotubes, taken from surgical specimens or biopsies.